湖南中医药大学学报2012，Vol.32Issue(10)：55-57,3.DOI:10.3969/j.issn.1674-070X.2012.10.025.055.03
CIK细胞治疗晚期恶性肿瘤的临床研究
Clinical study of cytokine-induced killer cell transfusion in the treatment of advanced malignant tumor
任庆 1熊锐华 1田秀荣 1罗克品 1周欣1
作者信息
- 1. 中国人民解放军第181医院肿瘤治疗中心,广西桂林541002
- 折叠
摘要
Abstract
Objective The purpose of this study was to observe clinical efficacy of cytokine-induced killer cell(CIK) in the treatment of advanced malignant tumor. Methods A total of 42 patients with malignant tumor that can not be surgeryed or radiotherapyed and chemotherapy at all received CIK to therapy. Such as T lymph cell subpopulation (CD3+、 CD4+、 CD8+、 CD16+CD56+,quality of life,short-term response and long-term rate was observed after therapy. Results A total of 42 patients can be evaluated the efficiency and toxicity. The response rates was 16.7%. CD3+、 CD4+、 CD8+、 CD16+CD56+ was obviously raised in all patients, Symptom and quality of life was received significant improve.,PFS was 8.1 months, OS was 12.8months.A few patients geted ferves in transfusion, The adverse reaction of patients was mild. Conclusion The cytokine-induced killer cell(CIK) that can improve clinical symptom and quality of life, prolong overall survival, furthermore no toxicities was clinical关键词
CIK细胞/恶性肿瘤/过继免疫治疗Key words
Cytokine-induced killer cell/ Advanced malignant tumor/Adoptive immunotherapy分类
医药卫生引用本文复制引用
任庆,熊锐华,田秀荣,罗克品,周欣..CIK细胞治疗晚期恶性肿瘤的临床研究[J].湖南中医药大学学报,2012,32(10):55-57,3.
